ARTICLE | Top Story
DNDN falls on interim analysis
January 11, 2002 8:00 AM UTC
Dendreon (DNDN) fell $3.05 (38%) to $5 on 6 million shares on Friday following the company's announcement that interim analysis of its Phase III study of its Provenge in patients with hormone-resistan...